Program
Phenytoin
Also written as “Phenytoin (Ascoli)”, “Dilantin Infatabs (Phenytoin)” and “Phenytoin: Study Drug”.
Its studies are mostly in Epilepsy · Seizures · Hepatitis C, led by 8 companies.
Drug pagePhenytoin: every studyMany companies study it; this page follows only the 10 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 30 open or running | phase 1since Apr 20, 2010 | Apr 20, 2010 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Feb 20, 2008 | Feb 20, 2008 | none ahead |
| Janssen Infectious Diseases BVBAits history only | 10 open or running | phase 1since Jul 4, 2012 | Jul 4, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Merckits history only | 10 open or running | phase 1since Mar 25, 2025 | Mar 25, 2025 | none ahead |
| Novartisits history only | 11 open or running | phase 1since Aug 18, 2026 | Aug 18, 2026 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Jun 14, 2024 | Jun 14, 2024 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 1since Jun 23, 2021 | Jun 23, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zydus Lifesciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 23, 2021First study: phase 1 study in HealthyFirst studyNCT04981704 · 74 enrolled · United States
TargetBeta
“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
The one study Zydus Lifesciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04981704Healthy · United States | 1 | Completed | Jun 30, 2021 | 74 |
How it is read
Names in the registry
- “Phenytoin”, 5 entries
- “Phenytoin (Ascoli)”, 1 entry
- “Dilantin Infatabs (Phenytoin)”, 1 entry
- “Phenytoin: Study Drug”, 1 entry
- “phenytoin”, 1 entry
Conditions, from the studies’ own filings
- Epilepsy, 3 studies
- Seizures, 1 study
- Hepatitis C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.